Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 946 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT06531798RecruitingPhase 4
Safety study of Breztri aerosphere in Indian COPD patients
This study tests a medication called Breztri aerosphere (a triple-combination inhaler) to see how safe and well-tolerated it is in Indian patients with COPD who have had recent flare-ups. It may help people who need better control of their breathing symptoms.
Dalgate, DrugjanAges 18 years+ - NCT07020741Recruiting
Stable isotope study in adults with obesity
This study uses a special test (stable isotopes) to learn about how adults with obesity process food and energy. It may help researchers understand weight and metabolism better.
Urbana, IllinoisAges 19–59 - NCT05277168RecruitingPhase 1/Phase 2
Study drug for advanced stomach or pancreatic cancer with Claudin 18.2
This trial tests the safety and side effects of SHR-A1904, and whether it can help people with advanced stomach or pancreatic cancer. To join, your tumor must have high “Claudin 18.2” protein, and you must meet several health and timing requirements.
Miami Beach, FloridaAges 18 years+ - NCT07697560RecruitingPhase 1
Safety of AH-008 in healthy volunteers
This trial tests a new medicine called AH-008 in healthy people to see if it's safe and how the body processes it. It is a first-in-human study with a single dose.
Salt Lake City, UtahAges 18–65 - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07481578Recruiting
Exercise and gut health study for active men
This study looks at how your training load affects your gut bacteria and how that relates to exercise performance and muscle health. It may help understand overreaching in healthy men.
Leuven, Vlaams BrabantAges 18–45 - NCT07204275RecruitingPhase 2/Phase 3
Testing povetacicept for primary membranous nephropathy
This study tests an investigational drug called povetacicept for people with primary membranous nephropathy, a kidney disease. Researchers want to see if it is safe and helps reduce protein in the urine.
Montgomery, AlabamaAges 18–75 - NCT07201467RecruitingPhase 1/Phase 2
KN060 for dialysis patients with kidney failure
This study tests an experimental drug called KN060, given to people with end-stage kidney disease on dialysis, to see if it is safe and helps with blood clotting. It may be an option if you are on stable dialysis and not at high risk for bleeding.
Beijing, Beijing MunicipalityAges 18–80 - NCT07267026RecruitingPhase 1
Safety study of the drug SK-09 in healthy adults
This trial tests a new medicine called SK-09 in healthy volunteers to see if it is safe and how the body processes it. The results will help decide the right dose for future studies.
Herston, QueenslandAges 18–55 - NCT07595458RecruitingPhase 1
Safety Study of JST-018 Immune Treatment in Healthy Adults
This is a first-in-human safety study testing a new experimental immune therapy called JST-018. Researchers want to see how safe it is, how well your body tolerates it, and how your body processes it when given as an injection.
Las Vegas, NevadaAges 18–55 - NCT07729839RecruitingPhase 1
Study of ADB116 injection for healthy volunteers
This trial tests a new medicine called ADB116 in healthy people to see how safe it is and how the body processes it. The results will help decide the right dose for future studies.
Guangzhou, GuangdongAges 18–45 - NCT07531745RecruitingPhase 1/Phase 2
ION337 gene therapy for children with Dravet syndrome
This study tests a new gene therapy called ION337 designed to treat Dravet syndrome, a severe childhood epilepsy caused by a SCN1A gene mutation. The therapy is given as a spinal fluid injection and aims to reduce seizures in children ages 2–12.
Ann Arbor, MichiganAges 2–12 - NCT06872125RecruitingPhase 3
Testing zorevunersen for Dravet syndrome
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Phoenix, ArizonaAges 2–17 - NCT06412120RecruitingPhase 4
Niraparib safety and metabolism study in Black women
This trial tests a new maintenance therapy called niraparib for Black women who have finished initial treatment for advanced ovarian cancer and are in remission or partial response. It aims to see if the drug is safe and how your body processes it.
Fort Lauderdale, FloridaAges 18 years+ - NCT07684235RecruitingPhase 3
Long-term study of a weight-loss drug for trial graduates
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
Daphne, AlabamaAges 18–99 - NCT07736638RecruitingPhase 1
Testing safety and tolerability of ABBV-859 in healthy adults
This trial studies a new drug called ABBV-859 in healthy volunteers to see how safe it is and how the body processes it. It helps doctors decide the right dose for future studies.
Anaheim, CaliforniaAges 18–65 - NCT07179640RecruitingPhase 1/Phase 2
Testing ALE1 for hypophosphatasia in healthy people and patients
This trial tests a new medicine called ALE1 for hypophosphatasia (HPP), a rare bone condition. It first checks safety in healthy volunteers, then tests if the medicine helps people with HPP.
WürzburgAges 18–50 - NCT07217067RecruitingPhase 2
Study of PKN605 for people with atrial fibrillation
This trial tests a new medicine called PKN605 for people with atrial fibrillation (irregular heartbeat). The goal is to see if it can safely help control heart rhythm. You will need to have had at least two AF episodes recently and meet other heart health criteria.
Tupelo, MississippiAges 18 years+ - NCT07483827RecruitingPhase 1
Testing CPV-104 safety in healthy people and C3G patients
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
ViennaAges 18 years+ - NCT06596681RecruitingEarly Phase 1
Study of GA for hard-to-treat nerve pain
This early-phase trial tests a new treatment called GA for people with hard-to-treat neuropathic pain that hasn't improved with standard therapies. The goal is to see if it is safe and tolerable.
Beijing, Beijing MunicipalityAges 18–65 - NCT07525960RecruitingPhase 1
Testing NDI-5001 for X-linked Nephrogenic Diabetes Insipidus
This study tests a new drug called NDI-5001 in adult men with a specific genetic form of nephrogenic diabetes insipidus (a condition where the kidneys cannot concentrate urine properly). The trial checks whether the drug is safe, how your body handles it, and whether it might help reduce excessive urination and thirst.
Jacksonville, FloridaAges 18–55 - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Omaha, NebraskaAges 18 years+ - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 946 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.